A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent <i>Clostridioides difficile</i> Infection in Pre-clinical Models.

A highly significant difference in animal survival for those given an optimized OraCAb formulation versus an untreated control group was observed.

also in 132,142 other papers

Although survival data between the two antibody ratios did not reach statistical significance in either study, the data generated from both studies indicates a better survival outcome and clinical benefit in the hamster model when animals were treated with the OraCAb formulation with a ratio of 3:1 anti-TxB4 to anti-TxA4 IgG.

also in 111,027 other papers